Yohanna Rossi

Dr. Yohanna Rossi

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2026 in Liver International
Verified
Journal Article
Open access
IVIsabelle Castro Vitor
Isabelle Castro Vitor
MTMilena Tome
Milena Tome
WAWellgner Fernandes Oliveira Amador
Wellgner Fernandes Oliveira Amador
ISIgor Boechat Silveira
Igor Boechat Silveira
MLMarina de Assis Bezerra Cavalcanti Leite
Marina de Assis Bezerra Cavalcanti Leite
RMRodrigo Vieira Motta
Rodrigo Vieira Motta
Background and Aims: Primary sclerosing cholangitis (PSC) is an immune‐mediated cholestatic liver disease. Liver transplantation (LT) remains the only definitive treatment for patients with advanced disease. However, recurrence of PSC (rPSC) after LT is still a significant clinical challenge. The aim of this study was to assess the prevalence and incidence of rPSC following transplantation and to identify factors associated with its occurrence. Methods: We conducted a systematic review and meta‐analysis of observational cohorts by searching PubMed, Embase and Cochrane for studies. Statistical analyses were conducted using R, applying a random‐effects model with 95% confidence intervals. Results: Twenty‐nine studies were included, comprising 4682 patients who underwent LT for PSC (63.7% male). Most data originated from Europe (51.7%) and North America (29.2%), with additional cohorts from Asia (13.7%), South America (2.8%) and Oceania (2.6%). The worldwide pooled prevalence of rPSC was 18.66% (95% CI 15.33–22.52; I 2 = 84%) between 1980 and 2024. As for the worldwide pooled incidence, rPSC occurred at 26.04 per 1000 person‐years (95% CI 19.30–32.78; I 2 = 76.1%). The continent with the highest rPSC prevalence was Oceania with 30.65% (95% CI 23.17–39.29; I 2 = 13.8%) and South America had the highest incidence with 39.97 per 1000 person‐years (95% CI 25.42–54.51). Younger recipient age (mean difference [MD] = 5.16 years, 95% CI 4.13–6.19; I 2 = 51.3%), male sex (risk ratio [RR] = 0.92, 95% CI 0.87–0.98; I 2 = 0%), post‐LT cyclosporine use (RR = 0.56, 95% CI 0.42–0.76; I 2 = 0%), acute rejection (RR = 0.64, 95% CI 0.49–0.83) and de novo IBD (RR = 0.63, 95% CI 0.40–0.99; I 2 = 0%) were associated with an increased risk of recurrence. Conclusions: Prevalence and incidence of rPSC post‐LT varied according to continents. Younger recipient age, male sex, de novo IBD, cyclosporine use post‐LT and acute rejection episodes were associated with a higher risk of recurrence. Trial Registration: PROSPERO ID: CRD420250645485

25 August 2025 in Gastroenterology Insights
Verified
Journal Article
Open access
PDF file
ISIgor Boechat Silveira
Igor Boechat Silveira
RRRodolfo Augusto Assis Rezende
Rodolfo Augusto Assis Rezende
CNCarlos Alberto Monteiro Leitão Neto
Carlos Alberto Monteiro Leitão Neto
YRYohanna Rossi
Yohanna Rossi
MLMarina de Assis Bezerra Cavalcanti Leite
Marina de Assis Bezerra Cavalcanti Leite
GCGuilherme Grossi Lopes Cançado
Guilherme Grossi Lopes Cançado
Background: Autoimmune cholestatic liver diseases (AICLDs), including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), are characterized by progressive biliary injury and cholestasis, leading to an impaired quantity/quality of life. Pruritus affects 20–70% of patients and is often refractory to current treatments. Ileal bile acid transporter (IBAT) inhibitors reduce bile acid reabsorption and may alleviate cholestatic pruritus. This systematic review and meta-analysis evaluates their efficacy and safety in adults with AICLD. Methods: Following PRISMA guidelines, we systematically searched PubMed, Embase, and Cochrane-CENTRAL for studies assessing IBAT inhibitors in adult AICLD patients with pruritus for ≥12 weeks. The primary outcome was the change in the 5-D Pruritus Scale. Secondary outcomes included sleep quality, serum bile acids, liver biochemistry, and safety. Heterogeneity was assessed using Cochrane Q and I2 statistics. Results: Three studies (n = 180) met inclusion criteria, including two RCTs and one single-arm study. Patients (78% female; 85% PBC; 77% linerixibat) showed a significant pruritus reduction (MD = −4.93, 95%CI [−6.26, −3.59], p < 0.0001), accompanied by improved sleep quality (MD = −8.12, 95%CI [−13.54, −2.70], p = 0.0033). Serum bile acids, FGF19, and autotaxin decreased significantly, with increased C4 levels. AST and GGT declined, while ALP, ALT, and bilirubin remained stable. Adverse events occurred in 89.7%, mainly diarrhea (22.7%), nausea (12.2%), and abdominal pain (18.2%); serious events were rare (2.2%). Conclusions: IBAT inhibitors significantly reduce pruritus and improve sleep in AICLD, with a favorable safety profile. These findings support their potential as a novel therapeutic option for cholestatic pruritus in adults with AICLD.

14 October 2025 in International Journal of Epidemiology
Verified
Journal Article
Closed access
YRYohanna Rossi
Yohanna Rossi
GBGabriel Bolner
Gabriel Bolner
FOFabiana Dolovitsch de Oliveira
Fabiana Dolovitsch de Oliveira
JDJonathan Costa Dall’aCqua
Jonathan Costa Dall’aCqua
VJVânio Antunes Do Livramento Junior
Vânio Antunes Do Livramento Junior
CDCícero Armídio Gomes Dias
Cícero Armídio Gomes Dias
Background: There is no consensus on the efficacy of Bacillus Calmette–Guérin (BCG) revaccination. Because of this, we aimed to compare the effect of BCG revaccination with no revaccination in preventing tuberculosis (TB) disease. Methods: We searched PubMed, Embase, and the Cochrane Library databases from inception to December of 2023 for studies that compared BCG revaccination with no revaccination or placebo for this systematic review and meta-analysis. Outcomes of interest were incidence of TB disease, pulmonary TB and extrapulmonary TB. We pooled odds ratios (ORs) with 95% confidence interval (CI) using a random-effects model in R statistical software version 4.3.1. Heterogeneity was assessed with I2 statistics. Results: Five studies, involving 1 012 007 patients, of whom 501 597 (49.56%) were revaccinated with BCG, were included in the meta-analysis. There was a benefit in tuberculosis disease incidence in patients who received revaccination compared to patients who did not (OR 0.89; 95% CI: 0.81–0.98; P = .019; I2 = 53%) in the randomized controlled trials. When including observational studies, we found the same trend (OR 0.90; 95% CI: 0.77–1.05; P = .124; I2 = 26%) as well as in preventing against both extrapulmonary (OR 0.82; 95% CI: 0.38–1.76; P = .375; I2 = 24%) and pulmonary (OR 0.93; 95% CI: 0.86–1.01; P = .062; I2 = 0%) cases. Conclusions: BCG revaccination was associated with a slight decrease in the incidence of tuberculosis, pulmonary tuberculosis, and extrapulmonary tuberculosis.

25 December 2025 in Neurodegenerative Disease Management
Verified
Journal Article
Closed access
MCMurilo Marmori Cruccioli
Murilo Marmori Cruccioli
PCPedro Henrique Teixeira Carneiro
Pedro Henrique Teixeira Carneiro
JPJorge Ferreira Jasmineiro Pitanga
Jorge Ferreira Jasmineiro Pitanga
YRYohanna Rossi
Yohanna Rossi
LSLeticia Torres da Silva
Leticia Torres da Silva
FSFilipe P. Sarmento
Filipe P. Sarmento
Fatigue affects up to 95% of individuals with multiple sclerosis (MS), significantly impairing daily functioning. Management is multidisciplinary, and although amantadine lacks U.S. FDA approval for this indication, it remains the most commonly prescribed pharmacologic option despite inconsistent supporting evidence. This systematic review and meta-analysis evaluated the effectiveness of amantadine for MS-related fatigue. We searched MEDLINE, EMBASE, and Web of Science for randomized controlled trials (RCTs) comparing amantadine to placebo in the treatment of MS-related fatigue. Statistical analyses were conducted using R. Standardized mean differences (SMDs) and odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to assess fatigue severity and adverse effects incidence, respectively. A random-effects model was applied to all analyses. A total of nine RCTs were included, involving 601 patients, 66% of whom received amantadine. Amantadine use was not associated with a significant reduction in fatigue severity compared to placebo (SMD -0.22; [95% CI -0.72; 0.27]; p = 0.37). However, it was associated with higher odds of insomnia (OR = 2.33; [95% CI 1.27; 4.29]; p = 0.006). This meta-analysis suggests that amantadine is not effective for treating MS-related fatigue and is associated with an increased risk of adverse effects, particularly insomnia. These results cast doubt on its continued first-line use.